CXCL12 and B-cell chronic lymphocytic leukemia: On the other hand, the capability of CXCL12 to activate JAK2 and the inhibitory effect of JAK2 inhibitors on integrin affinity up regulation and mediated rapid adhesion clearly suggest that no mutations negatively affecting JAK2 kinase activity occur in B-CLL.